FL-AR and AR-V7 assessment in PBMC and circulating tumor cells (CTC) from PCa patients treated with abiraterone (AA), enzalutamide (E), or taxanes found that high PBMC AR-V7 levels correlate with worse AA/E and better taxane responses. Here, AR is linked to neoplasm.